pharm exam 4 medication Flashcards
Glucagon injectable (90º) (thigh or butt or stomach) (SQ, IM, IV)
MOA: raises blood sugar through activation of hepatic glucagon receptors, stimulating glycogenolysis and the release of glucose
indication: treat severe hypoglycemia, usually to people who are passed out, EMERGENT
SE: nausea, vomit, hyperglycemia, toxic effect can be hypokalemia
NI/CE:
CI:
aspart (novolog) (insulin meds)
rapid-acting, onset:15-30 mins, peak: 1-3 hours, duration: 3-5 hours, administer within 15 minutes before meal, side effects hypoglycemia, hypokalemia
humulin R and regular insulin (insulin meds)
short acting, onset: 30 minutes, peak: 3 hours, duration: 8 hours, administer 30 minutes before meal, side effects: hypoglycemia and hypokalemia
humulin NPH (insulin meds)
intermediate acting, onset: 1-2 hours, peak: 6 hours, duration: up to 24 hours, administer once or twice daily, side effects: hypoglycemia, hypokalemia
glargine (lantus) (insulin meds)
long-acting, onset:3-4 hours, peak: none, duration: >24 hours, administer once daily, side effects: hypoglycemia and hypokalemia
Glipizide oral (Class: Sulfonylurea)
MOA: The beta cell of the pancreas secretes insulin has a sulfonylurea receptor. When stimulated the receptor causes the beta cell to release insulin
indication: lower sugar come down
SE: hypoglycemia
NI/CE:
CI:
Metformin oral (Class: Biguanide)
MOA:
indication:type 2 diabetes
SE: nausea, diarrhea, bloating
NI/CE:
CI:
Sitagliptin (Januvia) oral (Class: DPP4 inhibitor)
MOA:
indication: incretin modulator, help lower blood sugar, type 2
SE:weight, hypoglycemia, acute pancreatitis, upper respiratory infections, serious skin reactions
NI/CE: medications should be used with caution in
clients with renal disease
CI:
Empagliflozin (Jardiance) oral (Class: SGLT2 inhibitor)
MOA: inhibits SGLT2, which transports sodium-
glucose, so it reducing glucose and sodium
reabsorption, incr. urinary glucose excretion and
sodium delivery to distal tubule
indication: help lower blood sugar type 2
SE: Glucosuria, increased urination.
May cause serious urinary tract infections
NI/CE:
CI: Patients with decreased renal
function
advantages: weight loss and decrease CV risks
Semaglutide (Wygovy) injectable (Class: GLP-1 agonists)
MOA: GLP-1 receptor in the brain makes patient feel more full after a meal
indication: weekly injectable, incretin analogs, with a reduced calorie diet and increased physical activity
SE: diarrhea, nausea, vomit, headaches, dizziness, increased sweating, indigestion, constipation, loss of appetite, BLACK BOX WARNING: thyroid cancer
NI/CE:
CI:
Prednisone (PO) glucocorticoids
MOA:
indication: Short-term to reduce inflammation. Long- term for immunosuppression
SE: imbalances, increase blood glucose, muscle weakness, peptic ulcers, thin fragile skin, cushings syndrome, mask signs, poor healing
NI/CE:
CI: never stop abruptly, lowest dose possible, treatment for osteoporosis and blood glucose levels, adrenal suppression, untreated systemic infections
Methylprednisolone (IV) glucocorticoids
MOA:
indication: Short-term to reduce inflammation. Long-term for immunosuppression
SE: imbalances, increase blood glucose, muscle weakness, peptic ulcers, thin fragile skin, cushings syndrome, mask signs, poor healing
NI/CE:
CI: never stop abruptly, lowest dose possible, treatment for osteoporosis and blood glucose levels, adrenal suppression, untreated systemic infections
Fludrocortisone (mineralocorticoid)
MOA:
indication: Aldosterone replacement in
Addison’s disease
SE: retention of sodium and water, hypertension, edema, cardiac enlargement, CHF, potassium loss, hypokalemic alkalosis
NI/CE: monitor disease or stress, surgery, infection, trauma
CI:
Levothyroxine
MOA:
indication: hypothyroidism
SE: (we are replacing thyroid hormone, so SE might show signs of hyperthyroidism), nervousness, tremors, insomnia, tachycardia, palpitations, dysrhythmias, angina, shortness of breath
NI/CE:
CI:
Propylthiouracil (PTU)
MOA: Block synthesis of thyroid hormones
indication: hyperthyroidism
SE:
NI/CE: monitor cardiac, hypothyroidism, rash, N/V agranulocytosis and lupus
CI:
Calcitonin
MOA:
indication: osteoporosis
SE:
NI/CE:
CI:
Trimethoprim-sulfamethoxazole
MOA: Inhibit bacterial synthesis
indication: Uncomplicated UTI, Standard therapy in women
SE:
NI/CE:
CI:
Alendronate (biphosphonate)
MOA: Inhibits osteoclast-mediated bone
resorption. Reverses bone loss and decreases risk
of fracture
indication: Enhances bone mineral density in
osteoporosis
SE:
NI/CE:
CI:
Antacids - calcium carbonate (Tums)
MOA: Neutralize stomach acid and elevate pH
indication: Symptomatic relief of heartburn, acid indigestion and upset stomach
SE: Constipation, Hypercalcemia, Rebound acidity when stopped
NI/CE: come in tables, chewable, capsules and liquid, It can be taken three to four times a day, Do not administer within 1-2 hours or other medications, Drink a full glass of water after administration
CI: Kidney disease, GI obstruction
Histamine-2 (H2) receptor antagonist - Famotidine
MOA: Block histamine-2 receptor sites of parietal cell which reduces hydrochloric acid
indication: Heartburn, GERD, Peptic ulcer disease, erosive esophagitis, Adjunct treatment for upper GI bleeding
SE: Constipation or diarrhea, CNS effects (headaches or dizziness)
NI/CE: Available over the counter, but given IV in the hospital setting, Take 15-60 minutes before eating or
drinking
CI:
PPI – pantoprazole
MOA: Blocks the secretion of hydrochloric
acid at the proton pump
indication: GERD, erosive esophagitis, Prophylactic with surgery, In combination with antibiotics for H.Pylori infection, Short-term treatment of active
duodenal ulcers
SE: Headache, Abdominal pain, diarrhea or constipation, Acute renal dysfunction, Long-term: Osteoporosis & bone fracture, Potential zinc, magnesium, or B12 deficiency, Immediately report signs of bleeding ulcers such as coughing/vomiting of blood
NI/CE: Available orally, with an NG tube, or as IV injection in the hospital setting, Can be taken with or without food
CI: